Ancient Mammal Immune Peptides Reconstructed to Reveal 160 Million Years of Evolutionary Defense
University of Oregon researchers reconstructed ancestral versions of lactoferricin, an antimicrobial peptide found in mammalian fluids, to trace its evolution over 160 million years. By synthesizing extinct forms, they demonstrated how minor amino-acid changes significantly enhanced the peptide's ability to kill bacteria like Pseudomonas aeruginosa and Staphylococcus aureus. The study highlights that a single mutation can drastically alter immune defense potency, offering insights for designing new antimicrobial therapies.
Key points
- Researchers at the University of Oregon used ancestral sequence reconstruction to recreate lactoferricin peptides from extinct placental mammal ancestors dating back approximately 160 million years.
- The study compared 376 vertebrate sequences to infer the evolution of the 25-amino-acid lactoferricin region, identifying three ancestral forms labeled AncLFcin1, AncLFcin2, and AncLFcin3.
- Experimental testing showed that while early ancestral forms had limited antimicrobial activity, later versions became significantly more potent, with modern bovine lactoferricin showing the strongest consistent results against bacteria.
- A single amino-acid substitution, specifically arginine replacing glutamine at position 8, was identified as necessary and sufficient to dramatically increase antimicrobial activity against Pseudomonas aeruginosa.
- The findings suggest that evolution is not a linear progression toward strength, as some ancestral forms were more effective against specific bacteria than modern human versions, providing a roadmap for engineering new antimicrobial peptides.
Background
This research builds on previous understanding of innate immunity and the role of iron-binding proteins like lactoferrin in microbial defense. While earlier studies focused on the immediate function of lactoferrin in binding iron to starve microbes, this work delves into the historical evolution of its antimicrobial peptide region. It complements recent discussions on vaccine-induced immune changes, such as those observed with the Shingrix vaccine, by exploring how natural selection has shaped molecular defenses over geological timescales rather than recent medical interventions.
Why it matters
Understanding the evolutionary trajectory of antimicrobial peptides provides a blueprint for designing new therapeutics to combat antibiotic-resistant bacteria. By identifying specific mutations that enhance bacterial killing, scientists can engineer more effective peptides. However, the research also cautions that bacteria can evolve resistance to these natural defenses, emphasizing the need for a deep understanding of evolutionary dynamics to anticipate future weaknesses in antimicrobial strategies.
What to watch
Researchers plan to investigate whether resurrected or engineered enhanced antimicrobial peptides can be developed into therapeutics. Future studies will likely focus on optimizing peptide stability and efficacy, as current antimicrobial peptides are less stable than conventional antibiotics and can break down quickly in the body. The team aims to use the identified evolutionary mutations to guide the design of next-generation antimicrobial molecules.
Want the full story? Read the original reporting
Read on The Brighter Side of News